natgillin/translations-raw huggingface dataset:
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Ta sklep nadomešča Sklep 2013/129/EU [2], ki ga je Sodišče Evropske unije (v nadaljnjem besedilu: Sodišče) razglasilo za ničnega v sodbi z dne 16. aprila 2015 v Zadevi C-317/13 [3].
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 4-methylamphetamine under control across the Union.
V navedeni sodbi je Sodišče odločilo, da se učinki Sklepa 2013/129/EU ohranijo v veljavi do začetka veljavnosti novih aktov, s katerimi bodo nadomeščeni stari.
This Decision replaces Council Decision 2013/129/EU [2] which was annulled by the Court of Justice of the European Union (‘the Court’) by its judgment of 16 April 2015 in Case C-317/13 [3].
Zato Sklep 2013/129/EU preneha učinkovati z začetkom veljavnosti tega sklepa.
In that judgment, the Court maintained the effects of Decision 2013/129/EU until the entry into force of new acts intended to replace it.
Zaradi neprekinjene veljavnosti nadzornih ukrepov za 4-metilamfetamin po vsej Uniji ta sklep ne bi smel posegati v obveznosti držav članic v zvezi z roki za uvedbo nadzornih ukrepov in kazenskih sankcij za navedeno novo psihoaktivno snov v nacionalno zakonodajo, kot je določeno v členu 2 Sklepa 2013/129/EU.
Therefore, as of the day of entry into force of this Decision, Decision 2013/129/EU ceases to produce effects.
Sklep 2005/387/PNZ je za Dansko zavezujoč, zato sodeluje pri sprejetju in uporabi tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ.
In order to ensure the continuity of control measures across the Union with regard to 4-methylamphetamine, this Decision should be without prejudice to the obligations of the Member States relating to the time limit for subjecting that new psychoactive substance to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2013/129/EU.
Sklep 2005/387/PNZ je za Irsko zavezujoč, zato sodeluje pri sprejetju in uporabi tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ.
Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
Sklep 2005/387/PNZ ni zavezujoč za Združeno kraljestvo, zato ne sodeluje pri sprejetju tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ in zanj ni zavezujoč niti se v njem ne uporablja –
Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
SPREJEL NASLEDNJI SKLEP:
The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision which implements Decision 2005/387/JHA and is not bound by it or subject to its application,
Člen 1
HAS ADOPTED THIS DECISION:
Za novo psihoaktivno snov 4-metilamfetamin se uvedejo nadzorni ukrepi v vsej Uniji.
The new psychoactive substance 4-methylamphetamine shall be subjected to control measures across the Union.
Sklep 2013/129/EU preneha učinkovati z dnem začetka veljavnosti tega sklepa, vendar brez poseganja v obveznosti držav članic v zvezi z roki za uvedbo nadzornih ukrepov in kazenskih sankcij za 4-metilamfetamin v nacionalno zakonodajo, kot določa člen 2 Sklepa 2013/129/EU.
Decision 2013/129/EU ceases to produce effects from the date of entry into force of this Decision, without prejudice to the obligations of the Member States relating to the time limit for subjecting 4-methylamphetamine to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2013/129/EU.
Ta sklep začne veljati dan po objavi v Uradnem listu Evropske unije.
Article 3
Ta sklep se uporablja v skladu s Pogodbama.
This Decision shall enter into force on the day following that of its publication in the Official Journal of the European Union.
V Luxembourgu, 8. oktobra 2015
This Decision shall apply in accordance with the Treaties.
Za Svet
Done at Luxembourg, 8 October 2015.
Predsednik
For the Council
UL L 127, 20.5.2005, str. 32.
The President
Sklep Sveta 2013/129/EU z dne 7. marca 2013 o uvedbi nadzornih ukrepov za 4-metilamfetamin (UL L 72, 15.3.2013, str. 11).
OJ L 127, 20.5.2005, p. 32.
Sodba sodišča z dne 16. aprila 2015.
Council Decision 2013/129/EU of 7 March 2013 on subjecting 4-methylamphetamine to control measures (OJ L 72, 15.3.2013, p. 11).
Osem držav članic je v skladu s svojimi obveznostmi na podlagi Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971 v okviru zakonodaje na področju drog uvedlo nadzorne ukrepe za to snov.
Judgment of the Court of Justice of 16 April 2015, Parliament v Council, C-317/13, ECLI:EU:C:2015:223.
Dve drugi državi članici za snov uporabljata generično opredelitev za fenetilamin iz nacionalnih zakonodaj, medtem ko ena država članica snov nadzoruje v skladu s svojo zakonodajo na področju zdravil.
Council Implementing Decision (EU) 2015/1875
Izvedbeni sklep Sveta (EU) 2015/1875
on subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures
o uvedbi nadzornih ukrepov za 4-jodo-2,5-dimetoksi-N-(2-metoksibenzil)fenetilamin (25I-NBOMe), 3,4-dikloro-N-[[1-(dimetilamino)cikloheksil]metil]benzamid (AH-7921), 3,4-metilendioksipirovaleron (MDPV) in 2-(3-metoksifenil)-2-(etilamino)cikloheksanon (metoksetamin)
Risk Assessment Reports on the new psychoactive substances 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) were drawn up in accordance with Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and were subsequently submitted to the Commission and to the Council on 23 April 2014.
Poročila o oceni tveganja glede novih psihoaktivnih snovi 4-jodo-2,5-dimetoksi-N-(2-metoksibenzil)fenetilamin (25I-NBOMe), 3,4-dikloro-N-[[1-(dimetilamino)cikloheksil]metil]benzamid (AH-7921), 3,4-metilendioksipirovaleron (MDPV) in 2-(3-metoksifenil)-2-(etilamino)cikloheksanon (metoksetamin) so bila pripravljena v skladu s Sklepom 2005/387/PNZ na posebnem sestanku razširjenega znanstvenega odbora Evropskega centra za spremljanje drog in zasvojenosti z drogami (EMCDDA) ter so bila nato 23. aprila 2014 predložena Komisiji in Svetu.
NBOMe, AH-7921, MDPV and methoxetamine had not been under assessment at the United Nations' level by the time the risk assessment was requested at Union level, but they were evaluated in June 2014 by the Expert Committee on Drug Dependence of the World Health Organization.
Na ravni Združenih narodov 25I-NBOMe, AH-7921, MDPV in metoksetamin niso bili predmet ocenjevanja do časa, ko je bila ocena tveganja zaprošena na ravni Unije, vendar je junija 2014 oceno teh snovi pripravil Strokovni odbor za odvisnost od drog v okviru Svetovne zdravstvene organizacije.
NBOMe, AH-7921, MDPV and methoxetamine have no established or acknowledged human or veterinary medical use.
Uporaba 25I-NBOMe, AH-7921, MDPV in metoksetamina v humani ali veterinarski medicini ni uveljavljena ali priznana.
Apart from their use in analytical reference materials, in scientific research investigating their chemistry, pharmacology and toxicology as a result of their emergence on the drug market and, in the case of 25I-NBOMe, also in the field of neurochemistry, there is no indication that they are being used for other purposes.
Ni znakov, da bi se poleg uporabe v analitičnih referenčnih materialih, v znanstvenih raziskavah, namenjenih proučitvi njihovih kemijskih, farmakoloških in toksikoloških lastnosti zaradi pojava teh snovi na trgu z drogami, v primeru 25I-NBOMe pa tudi nevrokemijskih lastnosti, te snovi uporabljale za druge namene.
NBOMe is a potent synthetic derivative of 2,5-dimethoxy-4-iodophenethylamine (2C-I), a classical serotonergic hallucinogen, which was subject to risk assessment and to control measures and criminal sanctions at Union level from 2003 by virtue of Council Decision 2003/847/JHA [2].
NBOMe je močan sintetični derivat snovi 2,5-dimetoksi-4-jodofenetilamin (2C-I), klasičnega serotoninergičnega halucinogena, za katerega so bili od leta 2003 po opravljeni oceni tveganja na podlagi Sklepa Sveta 2003/847/PNZ [2] uvedeni nadzorni ukrepi in kazenske sankcije na ravni Unije.
The specific physical effects of 25I-NBOMe are difficult to determine because there are no published studies assessing its acute and chronic toxicity, its psychological and behavioural effects, and dependence potential, and because of the limited information and data available.
Posebne fizične učinke 25I-NBOMe je težko določiti, saj ni objavljenih študij, ki bi ocenjevale njegovo akutno in kronično toksičnost, njegove psihične in vedenjske učinke ter možnosti za povzročanje odvisnosti in ker so na voljo le omejene informacije in podatki.
Clinical observations of individuals who have used this substance suggest that it has hallucinogenic effects and has the potential for inducing severe agitation, confusion, intense auditory and visual hallucinations, aggression, violent accidents and self-induced trauma.
Klinična opazovanja posameznikov, ki so zaužili to snov, kažejo, da ima 25I-NBOMe halucinogene učinke in da lahko povzroči hudo tresenje, zmedenosti, intenzivne avditivne in vizualne halucinacije, agresijo, nasilne incidente in samopoškodbe.
Twenty-two Member States and Norway have reported to the EMCDDA and to the European Police Office (Europol) that they reported detection of 25I-NBOMe.
Evropskemu centru za spremljanje drog in zasvojenosti z drogami in Evropskemu policijskemu uradu (Europol) je 22 držav članic in Norveška poročalo o odkritjih 25I-NBOMe.
No prevalence data is available on the use of 25I-NBOMe, but the limited information that exists suggests that it may be consumed in a wide range of settings, such as at home, in bars, in nightclubs and at music festivals.
Podatkov o razširjenosti uporabe 25I-NBOMe ni, vendar se po obstoječih omejenih informacijah ta nova psihoaktivna snov uživa v najrazličnejših okoljih, na primer doma, v barih, nočnih klubih in na glasbenih festivalih.
NBOMe is openly marketed and sold on the internet as a ‘research chemical’ and information obtained from seizures, collected samples, user websites and internet retailers suggests that it is being sold as a drug in its own right and also marketed as a ‘legal’ replacement for LSD.
NBOMe se javno trži in prodaja prek spleta kot „kemikalija za raziskave“, informacije na podlagi zasegov, zbranih vzorcev, spletnih strani uporabnikov in spletnih trgovcev na drobno pa kažejo, da se prodaja kot samostojna droga, trži pa se tudi kot „zakoniti“ nadomestek za LSD.
The EMCDDA identified more than 15 internet retailers selling this substance, who may be based within the Union and China.
EMCDDA je odkril več kot 15 spletnih trgovcev na drobno, ki to snov prodajajo in bi lahko imeli sedež v Uniji in na Kitajskem.
The Risk Assessment Report reveals that there is limited scientific evidence available on 25I-NBOMe and points out that further research would be needed to determine the health and social risks that it poses.
Po poročilu o oceni tveganja je o 25I-NBOMe na voljo malo znanstvenih dokazov, zato so potrebne nadaljnje raziskave, da bi se ugotovila zdravstvena in socialna tveganja zaradi te snovi.
However, the available evidence and information provides sufficient ground for subjecting 25I-NBOMe to control measures across the Union.
Vendar so že razpoložljivi dokazi in informacije zadostna podlaga za uvedbo nadzornih ukrepov za 25I-NBOMe v vsej Uniji.
Given that six Member States control 25I-NBOMe under national legislation complying with the obligations of the 1971 United Nations Convention on Psychotropic Substances, and that seven Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would help protect against the risks that its availability and use can pose.
Ker je v šestih državah članicah uveden nadzor za 25I-NBOMe na podlagi nacionalne zakonodaje, ki je usklajena z obveznostmi iz Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971, in ker sedem držav članic izvaja nadzor z drugimi zakonodajnimi ukrepi, bi uvedba nadzornih ukrepov za to snov po vsej Uniji pripomogla k preprečevanju nastanka ovir v čezmejnem sodelovanju na področju kazenskega pregona in pravosodja ter bi zagotovila zaščito pred tveganji, ki lahko izhajajo iz razpoložljivosti in uporabe te snovi.
It can be easily confused with ‘doxylamine’, an antihistaminic medicine with sedative-hypnotic properties, which could lead to unintentional overdoses.
Zlahka ga je mogoče zamenjati z „doksilaminom“, antihistaminikom, ki ima lastnosti sedativa in hipnotika, zaradi česar obstaja nevarnost nenamernega zaužitja prevelikih odmerkov.
The specific physical effects of AH-7921 are difficult to determine because there are no published studies assessing its acute and chronic toxicity, its psychological, behavioural effects, and dependence potential, as well as the limited information and data available.
Posebne fizične učinke AH-7921 je težko določiti, saj ni objavljenih študij, ki bi ocenjevale njegovo akutno in kronično toksičnost, njegove psihične in vedenjske učinke ter možnosti za povzročanje odvisnosti, na voljo pa so le omejene informacije in podatki.
In addition to self-experimentation with AH-7921, as well as ‘recreational use’, some of the users report self-medicating with this new drug to relieve pain, others to alleviate withdrawal symptoms due to the cessation of the use of other opioids.
Podatkov o razširjenosti uporabe AH-7921 ni, vendar po razpoložljivih informacijah ni splošno razširjen, sicer pa se uporablja v domačem okolju.
This may indicate a potential of AH-7921 to spread among the injecting opioid population.
V treh državah članicah je bilo med decembrom 2012 in septembrom 2013 zabeleženih 15 smrtnih primerov, pri katerih je bila v vzorcih, odvzetih po smrti, ugotovljena prisotnost AH-7921 samega ali v kombinaciji z drugimi snovmi.
There is no prevalence data on the use of AH-7921, but the information available suggests that it is not widely used, and that when it is used, that use is in the home environment.
Čeprav ni možno z gotovostjo določiti vloge AH-7921 pri vseh teh smrtnih primerih, je bil ta v nekaterih primerih izrecno naveden kot vzrok smrti.
15 fatalities were recorded in three Member States between December 2012 and September 2013 where AH-7921, alone or in combination with other substances, was detected in post-mortem samples.
V zvezi z AH-7921 je ena država članica poročala o šestih zastrupitvah brez smrtnega izida.
While it is not possible to determine with certainty the role of AH-7921 in all of those fatalities, in some cases it has been specifically noted in the cause of death.
Ni razpoložljivih informacij o socialnih tveganjih v zvezi z AH-7921.
One Member State reported six non-fatal intoxications associated with AH-7921.
Po poročilu o oceni tveganja je o AH-7921 na voljo malo znanstvenih dokazov, zato so potrebne nadaljnje raziskave, da bi se ugotovila zdravstvena in socialna tveganja zaradi te nove psihoaktivne snovi.
There is no information available on the social risks associated with AH-7921.
Vendar so razpoložljivi dokazi in informacije zadostna podlaga za uvedbo nadzornih ukrepov za AH-7921 po vsej Uniji.
The Risk Assessment Report reveals that there is limited scientific evidence available on AH-7921 and points out that further research would be needed to determine the health and social risks that it poses.
Zaradi zdravstvenih tveganj, ki jih povzroča AH-7921, kot so bila dokumentirana ob ugotovitvi njegove prisotnosti pri več zabeleženih smrtnih primerih, zaradi dejstva, da ga lahko uporabniki zaužijejo nevede, in zaradi pomanjkanja njegove zdravstvene vrednosti ali uporabe, bi bilo treba za AH-7921 uvesti nadzorne ukrepe v Uniji.
However, the available evidence and information provides sufficient ground for subjecting AH-7921 to control measures across the Union.
Ker je v eni državi članici uveden nadzor za AH-7921 na podlagi nacionalne zakonodaje, ki je usklajena z obveznostmi iz Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971, pet držav članic pa nadzor izvaja z drugimi zakonodajnimi ukrepi, bi uvedba nadzornih ukrepov za to snov po vsej Uniji pripomogla k preprečevanju nastanka ovir v čezmejnem sodelovanju na področju kazenskega pregona in pravosodja ter bi zagotovila zaščito pred tveganji, ki lahko izhajajo iz razpoložljivosti in uporabe te snovi.
As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use of the substance, AH-7921 should be subjected to control measures across the Union.
MDPV je pirovaleronu podoben sintetični derivat katinona s substituiranim obročem, oba pa sta predmet nadzora v skladu s Konvencijo Združenih narodov o psihotropnih snoveh iz leta 1971.
Given that one Member State controls AH-7921 under national legislation complying with the obligations of the 1971 United Nations Convention on Psychotropic Substances, and that five Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would help protect against the risks that its availability and use can pose.
Zbiranje informacij o kronični in akutni toksičnosti, povezani z MDPV, ter psihičnih in vedenjskih učinkih ter o možnostih za povzročanje odvisnosti, ni standardizirano po vsej Uniji.
MDPV is a ring-substituted synthetic derivative of cathinone chemically related to pyrovalerone, which are both subject to control under the 1971 United Nations Convention on Psychotropic Substances.
Informacije, zbrane na podlagi objavljenih študij in potrjene s kliničnimi primeri, nakazujejo, da so psihofarmakološki učinki MDPV podobni učinkom kokaina in metamfetamina, vendar pa so njegovi učinki močnejši in trajnejši.
Information on the chronic and acute toxicity associated with MDPV, as well as on psychological and behavioural effects, and on dependence potential, is not collected uniformly across the Union.
Poleg tega je bilo ugotovljeno, da ima MDPV desetkrat večji potencial za povzročitev lokomotorne aktivacije, tahikardije in hipertenzije.
Information from published studies, confirmed by clinical cases, suggests that the psychopharmacological profile observed for MDPV is similar to that for cocaine and methamphetamine, albeit more potent and longer lasting.
Iz spletnih strani uporabnikov je razvidno, da lahko njegova akutna toksičnost povzroči škodljive učinke pri ljudeh, ki so podobni učinkom, povezanim z uživanjem drugih poživil.
Furthermore, MDPV was found to be ten times more potent in its ability to induce locomotor activation, tachycardia and hypertension.
Ti učinki vključujejo paranoidno psihozo, tahikardijo, hipertenzijo, diaforezo, težave z dihanjem, hudo tresenje, avditivne in vizualne halucinacije, hudo tesnobo, hipertermijo, nasilne izbruhe in motnje delovanja več organov.
Users' websites indicate that its acute toxicity can provoke adverse effects on humans, similar to those associated with other stimulants.
Od septembra 2009 do avgusta 2013 je bilo v osmih državah članicah in na Norveškem registriranih 108 smrtnih primerov, pri katerih je bila prisotnost MDPV ugotovljena v bioloških vzorcih, odvzetih po smrti, ali pa je bil ta eden od morebitnih vzrokov smrti.
These include paranoid psychosis, tachycardia, hypertension, diaphoresis, breathing problems, severe agitation, auditory and visual hallucinations, profound anxiety, hyperthermia, violent outbursts and multiple organ dysfunctions.
Osem držav članic je v zvezi z MDPV poročalo o skupaj 525 zastrupitvah brez smrtnega izida.
108 fatalities were registered in eight Member States and Norway between September 2009 and August 2013, where MDPV has been detected in post-mortem biological samples or implicated in the cause of death.
Od leta 2009 so štiri države članice poročale o prisotnosti MDPV, ki je bila ugotovljena v bioloških vzorcih v zvezi s prometnimi nesrečami na cestah, tudi s takimi s smrtnim izidom, ali z vožnjo pod vplivom drog.
A total of 525 non-fatal intoxications associated with MDPV have been reported by eight Member States.
Na trgu z drogami v EU je MDPV od novembra 2008, o zasegih več kilogramov MDPV pa je poleg Norveške in Turčije poročalo 27 držav članic.
The detection of MDPV has also been reported in biological samples related to fatal and non-fatal road traffic accidents, or driving under the influence of drugs, in four Member States since 2009.
MDPV se prodaja kot samostojna snov, vendar je bila njegova prisotnost ugotovljena tudi v kombinaciji z drugimi snovmi.
MDPV has been present on the Union drug market since November 2008, and 27 Member States, Norway and Turkey have reported multi-kilogram seizures of the substance.
Zelo je razširjen med spletnimi dobavitelji in trgovci na drobno, v specializiranih trgovinah in med uličnimi preprodajalci.
MDPV is being sold as a substance in its own right, but it has also been detected in combination with other substances.
Iz nekaterih pokazateljev je razvidno, da priprava tablet in distribucija te snovi v Uniji potekata do neke mere organizirano.
It is widely available from internet suppliers and retailers, ‘head shops’ and street-level dealers.
Poročilo o oceni tveganja navaja, da bi bilo treba opraviti nadaljnje raziskave za določitev zdravstvenih in socialnih tveganj, ki jih povzroča MDPV.
There are some indications that suggest a degree of organisation in the tableting and distribution of this substance in the Union.
Vendar razpoložljivi dokazi in informacije zagotavljajo zadostno podlago za uvedbo nadzornih ukrepov za MDPV po vsej Uniji.
The Risk Assessment Report reveals that further research would be needed to determine the health and social risks posed by MDPV.
Zaradi zdravstvenih tveganj, ki jih povzroča MDPV, kot so bila dokumentirana ob ugotovitvi njegove prisotnosti pri več zabeleženih smrtnih primerih, zaradi dejstva, da ga lahko uporabniki zaužijejo nevede, in zaradi pomanjkanja njegove zdravstvene vrednosti ali uporabe, bi bilo treba za MDPV uvesti nadzorne ukrepe v Uniji.
However, the available evidence and information provides sufficient ground for subjecting MDPV to control measures across the Union.
Ker je v 21 državah članicah uveden nadzor za MDPV na podlagi nacionalne zakonodaje, ki je usklajena z obveznostmi iz Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971, štiri države članice pa nadzor izvajajo z drugimi zakonodajnimi ukrepi, bi uvedba nadzornih ukrepov za to snov po vsej Uniji pripomogla k preprečevanju nastanka ovir v čezmejnem sodelovanju na področju kazenskega pregona in pravosodja ter bi zagotovila zaščito pred tveganji, ki lahko izhajajo iz razpoložljivosti in uporabe te snovi.
As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use of the substance, MDPV should be subjected to control measures across the Union.
Metoksetamin je arilcikloheksilamin, ki je kemično podoben ketaminu in fenciklidinu, za katerega je bil uveden mednarodni nadzor.